Human epidermal growth factor receptor 2 (HER2)/Neu is overexpressed in 20-30% of breast cancers and associated with aggressive phenotypes and poor prognosis. For deciphering the role of HER2/Neu in breast cancer, mouse mammary tumor virus (MMTV)-Her2/neu transgenic mice that develop mammary tumors resembling human HER2-subtype breast cancer have been established. Several recent studies have revealed that HER2/ Neu is overexpressed in and regulates self renewal of breast tumor-initiating cells (TICs). However, in the MMTV-Her2/neu transgenic mouse model, the identity of TICs remains elusive, despite previous studies showing supportive evidence for existence of TICs in Her2/neuinduced mammary tumors. Through systematic screening and characterization, we identified that surface markers CD49f, CD61 and ESA were aberrantly overexpressed in Her2-overexpressing mammary tumor cells. Analysis of these markers and CD24 detected anomalous expansion of the luminal progenitor population in preneoplastic mammary glands of Her2/neu transgenic mice, indicating that aberrant luminal progenitors originated in Her2induced mammary tumors. The combined markers, CD49f and CD61, further delineated the CD49f high CD61 highsorted fraction as a TIC-enriched population, which displayed increased tumorsphere formation ability, enhanced tumorigenicity both in vitro and in vivo and drug resistance to pacitaxel and doxorubicin. Moreover, the TIC-enriched population manifested increased transforming growth factor-b (TGFb) signaling and exhibited gene expression signatures of stemness, TGFb signaling and epithelial-to-mesenchymal transition. Our findings that self-renewal and clonogenicity of TICs were suppressed by pharmacologically inhibiting the TGFb signaling further indicate that the TGFb pathway is vital for maintenance of the TIC population. Finally, we showed that the integrin-b3 (CD61) signaling pathway was required for sustaining active TGFb signaling and self-renewal of TICs. We for the first time developed a technique to highly enrich TICs from mammary tumors of Her2/neu transgenic mice, unraveled their properties and identified the cooperative integrin-b3-TGFb signaling axis as a potential therapeutic target for HER2-induced TICs.
Introduction
According to the cancer stem cell (CSC) hypothesis, a variety of tumors may be initiated and maintained by a subpopulation of cells that exhibit characteristics of stem cells. In addition to driving carcinogenesis, these CSCs, also called tumor-initiating cells (TICs), may contribute to therapeutic resistance (Clarke et al., 2006) . Several recent studies have shown that human epidermal growth factor receptor 2 (HER2) may have a role in regulation of the TIC population. First, TICs of HER2overexpressing breast cancer cell lines express the highest HER2 levels in the bulk cell population (Magnifico et al., 2009) . Second, overexpression of HER2 in normal mammary epithelial cells increases the proportion of stem/progenitor cells (Korkaya et al., 2008) . Third, the HER2 inhibitor (trasuzumab or lapitinib) is able to specifically target this HER2overexpressing TIC population (Korkaya et al., 2008; Magnifico et al., 2009) . Finally, a decrease in TICs was observed in HER2-positive tumors of patients receiving the epidermal growth factor receptor/HER2 inhibitor treatment (Li et al., 2008) . These lines of evidence suggest that the HER2 signaling drives carcinogenesis through regulation of the mammary stem/progenitor cell population.
The role of Her2/neu in regulating TIC properties was also studied in the mouse mammary tumor virus (MMTV)-Her2/neu transgenic mouse model. Liu et al., (2007) first functionally identified the existence of TICs in primary mammary tumors of MMTV-Her2/neu transgenic mice, and Cicalese et al. (2009) showed that the self-renewal division of TICs is more frequent in Her2/neu-induced tumors than normal stem cells in their normal counterparts. Furthermore, the gene profiles of MMTV-Her2/neu mammary tumors are most congruent with the gene signature of luminal progenitor cells, suggesting that Her2-induced mammary tumors may be developed from altered mammary luminal progenitor cells (Lim et al., 2010) . Despite supportive evidence from these studies, currently there are no available methods developed for isolation or enrichment of TICs from Her2/neu-induced mammary tumors. Therefore, although MMTV-Her2/neu transgenic mice have been used as a Her2-mediated tumorigenic animal model for about two decades (Guy et al., 1992) , the identity of TICs in Her2/neu-induced mammary tumors remains largely unknown.
To identify and characterize the putative TICs in the MMTV-Her2/neu transgenic mouse model, we screened numerous putative stem/progenitor marker combinations to subdivide the primary mammary tumor cells and their derivative primary cell cultures. By analyzing these markers, we identified luminal progenitors potentially giving rise to Her2-induced TICs. Importantly, we found that the CD49f high CD61 high tumor cell subset represents a TIC-enriched population, and the cooperative integrin-b3-transforming growth factor (TGFb) signaling axis is vital for maintaining Her2-induced TICs. These findings, taken together, suggest that targeting of the cooperative integrin-b3-TGFb signaling could be developed for the TIC-targeting therapy to treat HER2/Neu-positive breast cancer patients.
Results

Identification of TIC biomarkers for Her2/neu-induced mammary tumors
To identify potential stem cell biomarkers and characterize molecular traits of stemness in Her2-induced mammary tumors, we performed gene expression profiling analysis of 26 putative stem cell markers and 5 epithelial lineage-specific markers (Supplementary Tables 1 and 2) on H6O5 cells derived from Her2induced mouse primary mammary gland tumors and NMuMG cells, a non-transformed mouse mammary epithelial cell line (Hynes et al., 1985) serving as a normal control for comparison. Before gene expression analysis, Her2/neu overexpression in H6O5 cells has been confirmed by western blot analysis and its levels were almost equivalent to those in primary Her2 tumors ( Supplementary Figure 1) . In all, 9 out of 26 analyzed genes were expressed at higher levels in H6O5 than in NMuMG, including Abcg2, CD49f, CD61, ESA, Nanog, Notch3, Oct3/4, Stat3 and Tp63 (Supplementary Table 2 and Figure 1a ). Among lineage-specific markers, H6O5 cells expressed slightly less mRNA levels of CD24 and the luminal marker keratin 18 (Krt18) and higher levels of myoepithelial markers, such as Krt5 and Krt14, than NMuMG cells ( Supplementary Table 2 ). To further validate that nine aberrantly overexpressed genes identified in H6O5 cells were not attributable to forced in vitro culture condition, we performed quantitative reverse transcriptase PCR analysis on two samples each of isolated in vivo normal epithelial cells from FVB/N mammary glands and tumor epithelial cells from primary Her2/neu mammary gland tumors. As shown in Figure 1b , eight out of nine genes (except Stat3) consistently showed aberrant overexpression in primary Her2/neu mammary tumor epithelial cells compared with age-matched normal FVB/N mammary epithelial cells.
Among these differentially expressed genes, CD49f (integrin-a6), CD61 (integrin-b3) and ESA have been identified and used as bona fide markers for the enrichment of normal and CSCs Asselin-Labat et al., 2007; Vaillant et al., 2008; Lim et al., 2010) . To validate quantitative reverse transcriptase PCR results and evaluate whether these selected markers can be potentially used to identify and enrich TICs, fluorescence-activated cell sorting (FACS) analysis was performed on H6O5 cells and two normal mammary epithelial cell lines (NMuMG and C127) to examine the expression status of selected markers, including CD49f, CD29, CD61, Sca1, CD24 and ESA (EpCAM). CD49f, CD61 and ESA were selected because of their aberrant overexpression in H6O5 cells and primary tumors (Figures 1a and b ). CD29 and Sca1 were also chosen, as they have been used as markers to identify normal and neoplastic mammary stem and/or progenitor cells (Welm et al., 2003; Shackleton et al., 2006; Stingl et al., 2006; Asselin-Labat et al., 2007) . CD24 was included in our study on the basis of the studies by Liu et al. (2007) , showing that only CD24 þ Her2/neu tumor cells are tumorigenic. As shown in Figure 1c , CD49f, CD61 and ESA were expressed at higher levels in H6O5 cells than in the control cell lines, consistent with the mRNA expression data (Figure 1a ). CD29 and CD24 were almost equivalently expressed between these three cell lines ( Figure 1c ). Sca1 was highly expressed in C127 cells compared with H6O5 and NMuMG cells ( Figure 1c ). Overall, these data suggest that CD49f, CD61 and ESA are potential candidates as TIC markers because of their differential expression in Her2/neu-transformed tumor cells compared with nontransformed mammary epithelial cells.
Her2/neu-induced tumors are potentially developed from the luminal progenitor population MMTV-Her2/neu transgenic mice develop undifferentiated adenocarcinomas after a long latency (6-12 months; Guy et al., 1992) . To identify the origin of Her2-transformed TICs, we examined changes in cellular subsets of preneoplastic mammary glands. The previous study showed that CD24 and CD49f can identify mammary stem cells (mammary repopulating units, MRUs) and progenitor cells (mammary colonyforming cells, Ma-CFCs) . We reproduced these data as shown in Figure 2a Figure 2 FACS analysis of CD49f, CD24, ESA and CD61 in normal mammary glands, MMTV-Her2/neu preneoplastic mammary glands and tumors. FACS analysis was performed to examine the protein expression of CD49f, CD24, ESA and CD61 on mammary glands of FVB/N mice, as well as Her2/neu transgenic mice and on primary mammary tumors arising in MMTV-Her2/neu transgenic mice. CD24 versus CD49f, as well as ESA versus CD49f, CD24 versus CD61 and CD49f versus CD61 are shown in a-c, respectively. Histogram analyses of CD49f and CD61 are shown in the bottom panels of subfigure a and b, respectively. FVB/N-M, control mammary gland; HER2-M, Her2/neu transgenic mouse mammary gland; NER2-T, Her2/neu tumor.
The identity of TIC in Her2-induced mammary tumors P-K Lo et al (Lin À CD24 high CD49f med/low cells) was aberrantly expanded in preneoplastic mammary glands of MMTV-Her2/neu transgenic mice compared with normal counterparts of wild-type FVB/N mice (9.8% vs 3.1%), which overlapped the majority (79.2%) of the primary tumor cell population (Figure 2a ). The percentage of the mammary stem cell population (Lin À CD24 med CD49f high , MRUs) remained unchanged in preneoplastic mammary glands of transgenic mice relative to wild-type mice (0.8% vs 0.7%). We also analyzed the FACS profiles of CD49f and ESA because of the recent findings that these two markers could delineate cellular subsets in human mammary glands (Lim et al., 2009 ). Analogous to the CD24CD49f combination, ESA and CD49f could define the MRU and Ma-CFC populations (Figure 2a , the middle panel). Again, the Lin À ESA high CD49 med/low Ma-CFC population, but not the Lin À ESA med CD49f high MRU population, was anomalously expanded in premalignant mammary glands of Her2/neu transgenic mice (Figure 2a ). The FACS patterns showing expansion of the Ma-CFC population in Her2/neu preneoplastic mammary glands ( Figure 2a ) were reproducible in multiple mice (n44; data not shown). Among Lin À CD24 þ mammary epithelial cells, the percentage of Lin À CD49f þ cells progressively increased with tumor development (wild type 24.3%, preneoplastic gland 36.8% and tumor 81.8%; Figure 2a , the bottom panel). According to the studies by Stingl et al. (2006) , Ma-CFCs preferentially express luminal markers such as Krt18 and Krt19, indicating that they are luminal progenitor cells. We also found that Ma-CFCs exhibited the ESA high profile, a typical luminal feature (Lim et al., 2009) . Therefore, our and other lines of evidence, taken together, suggest that the origin of Her2/neu-induced mammary tumor cells is derived from the aberrant luminal progenitor cells. We also analyzed the cellular subset expressing CD61 in combination with CD24 or CD49f during tumor development in MMTV-Her2/neu transgenic mice. Preneoplastic mammary glands exhibited a slight increase in both Lin À CD24 þ CD61 þ (1.7% vs 1.1%) and Lin À CD49f þ CD61 þ cells (1.6% vs 1.2%) compared with wild-type counterparts, but both Lin À CD24 þ CD61 þ (89.2%) and Lin À CD49f þ CD61 þ (89.9%) cell populations were drastically expanded in primary tumors (Figures 2b and c) . The expansion of Lin À CD24 þ CD61 þ and Lin À CD49f þ CD61 þ cells in primary tumors was mainly due to a dramatic increase in the Lin À CD61 þ cell population, and more importantly there was a significant, tumor-specific increase in the expression level of CD61 at the cellular level. Thus, the transition from preneoplasia to tumor formation is characterized by a significant increase in CD24/ESA/ CD49f/CD61-quadruple-positive cells ( Figure 2 ).
The CD49f high CD61 high subpopulation exhibits the CD24 high ESA high profile and TIC's characteristics According to the Figure 2 results, we identified CD49f, CD61, ESA and CD24 as potential TIC's makers, as they can be used to track the transformed transition from luminal progenitor cells to Her2-induced tumor cells. To ascertain which two-antigen combination is potential for identifying the TIC population, we performed FACS analysis of five different antigen combinations on in vitro cultured H6O5 cells, in vivo H6O5-derived xenograft tumors and primary Her2 mammary tumors. As shown in Figure 3a , the FACS profiles of H6O5-derived xenograft tumors were almost identical to those of primary Her2 tumors, demonstrating that the primary H6O5 line is a suitable cell model for studying Her2-induced primary mammary gland tumors. Among the FACS profiles of in vitro cultured H6O5 cells, only CD49f/CD61, ESA/CD61 and ESA/ CD49f were akin to those in xenograft and primary tumors ( Figure 3a ). The differences in CD24/CD61 and CD24/CD49f profiles between in vitro cultured tumor cells and in vivo tumors might be attributable to in vitro culture condition. For identifying both in vitro and in vivo TICs, CD49f, CD61 and ESA are suitable markers for further studies. However, because of very strong fluorescent staining of ESA in H6O5 cells, we preferred the CD49f/CD61 combination for the FACS gating in cell sorting analysis. To develop a promising FACS gating strategy, we used the CD49f/CD61 profile of NMuMG to set the quadrant threshold lines for defining three different subpopulations in H6O5 cells (Figure 3b ). These three subsets, CD49f high CD61 high , CD49f high CD61 low and CD49f low CD61 low , are 12-15%, 35-40% and 25-30%, respectively, of total cells. To investigate the relationship between these three gated populations and ESA/CD24 profiles, we performed four-color FACS analysis on H6O5 cells using antibodies against these four markers. As shown in Figure 3b , 89.9% of CD49f high CD61 high subset cells overlapped CD24 high ESA high compared with only 25.4% of CD49f low CD61 low subset cells. A strong correlation between these four potential stem/progenitor cell markers suggests that tumor cell types in Her2/neuinduced mammary tumors are heterogeneous and may be organized like a hierarchy proposed in the CSC model. This phenomenon has also been confirmed using isolated in vivo tumor cells (data not shown).
To address whether CD49f and CD61 are useful markers for enriching TICs, we examined tumorsphere formation abilities of these sorted fractions. The CD49f high CD61 high subpopulation exhibited the highest tumorsphere formation efficiency (2.8±0.6%) compared with CD49f high CD61 low and CD49f low CD61 low populations displaying much lower efficiencies (0.8±0.3% and 0.3±0.1%, respectively; Figure 4a ). The observed significant increase in tumorsphere formation ability indicates that TICs are enriched in the CD49f high CD61 high subpopulation.
Given that tumorigenicity is one of the hallmarks of TICs, we assessed the tumorigenic potential of the sorted cells with in vitro clonogenic and in vivo transplantation assays. As shown in Figure 4b , CD49f high CD61 high cells exhibited the highest clonogenic ability compared with other two subset cells. For in vivo transplantation assays, we transplanted serially diluted sorted subset cells from H6O5 or primary tumors, Table 1 ). The sorted cells from H6O5 manifested a similar trend of TIC frequencies (Table 1) . Therefore, TICs in MMTV-Her2/neu mammary tumors or in H6O5 cells were significantly enriched in the CD49f high CD61 high population. In addition to the highest frequency of TICs, the CD49f high CD61 high subpopulation conferred an earliest onset of tumor formation compared with other two populations (Figure 4c ). To address whether the CD49f high CD61 high subpopulation possesses the drugresistant characteristic of CSCs, clonogenic assays were performed on sorted CD49f high CD61 high and CD49f low CD61 low H6O5 cells treated with pacitaxel or doxorubicin. The identity of TIC in Her2-induced mammary tumors P-K Lo et al Indeed, CD49f high CD61 high cells were more resistant to these chemotherapeutic agents than CD49f low CD61 low cells (Figure 4d ). CSCs are endowed with the ability to self-renew indefinitely and differentiate into phenotypically diverse cells. To reveal whether the CD49f high CD61 high subpopulation exhibits these CSC features, we analyzed cellular subtypes in xenograft tumors derived from these three sorted cell fractions. The tumors derived from the CD49f high CD61 high subpopulation were composed of cell populations similar to the original primary tumors, demonstrating that the CD49f high CD61 high subpopulation is able to self-renew its own population (12.2±0.7%) and also convert into other cell populations during tumor formation ( Figure 5) . In contrast, the tumors derived from CD49f high CD61 low and CD49f low CD61 low fractions contained significantly lower percentages of the CD49f high CD61 high subpopulation (7.9 ± 0.6% and 1.6±0.6%, respectively; Figure 5 ), indicating that these two sorted cell fractions contain less CSCs than the CD49f high CD61 high fraction. These results show that CD49f high CD61 high cells exhibit CSC traits of selfrenewal and regeneration of heterogeneity of primary tumors. (c) CD49f high CD61 high cells showed the early onset of in vivo tumor formation. A total of 5000 sorted H6O5 cells were transplanted into the mammary glands of syngeneic mice. The tumor formation was monitored for 13 weeks, and then mice were killed and dissected. The dissected tumors were photographed and shown in the top panel. (d) CD49f high CD61 high cells manifest drug resistance to pacitaxel and doxorubicin. Sorted H6O5 cells were treated with pacitaxel (2 nM) for 24 h and doxorubicin (25 ng/ml) for 10 h, and then 5000 drug-treated cells were plated in a 6-cm cell culture dish for clonogenic assays. Two weeks later, cell colonies were stained with crystal violet and colony numbers were counted for determining the percentages of clonogenic survival (drug-treated cells relative to vehicletreated cells). The mean and s.d. of each drug-treated cell survival data set were derived from triplicate experiments. * , **Po0.05 indicates a statistically significant difference in clonogenic survival percentages of drug-treated CD49f high CD61 high cells compared with those of drug-treated CD49f low CD61 low cells.
The identity of TIC in Her2-induced mammary tumors P-K Lo et al
The TGFb signaling and expression of EMT genes are specifically activated in the CD49f high CD61 high subpopulation To further characterize TICs in Her2/neu tumors, gene expression profiling analysis was performed to examine expression of putative stem cell and differentiation marker genes. The CSC markers Abcg2 (Ishikawa and Nakagawa, 2009 ), Aldh1 (Ginestier et al., 2007) , CD133 (Wright et al., 2008) , Gli1 (Liu et al., 2006) and Tp63 (Hanker et al., 2010) were highly expressed in the CD49f high CD61 high subpopulation compared with other two sorted subpopulations (Figure 6a ). In contrast, the expression levels of differentiation marker genes such as Krt5, Krt6, Krt14 and Krt18 were lowest in CD49f high CD61 high cells (Figure 6b ). These data further confirm that the CD49f high CD61 high subpopulation is enriched for TICs with stem cell characteristics. The TGFb signaling has been known to have a critical role in regulating the pluripotency of human embryonic stem cells and CSCs via induction of an epithelialmesenchymal transition (EMT; James et al., 2005; Mani et al., 2008) . To examine the status of TGFb signaling in sorted cells, we analyzed the expression of several selected TGFb downstream responsive genes (Pai, Il6, Igfbp3 and Foxc2). Compared with CD49f low CD61 low cells, expression of Pai , Il6 (Park et al., 2003) , Igfbp3 (Kveiborg et al., 2001) and Foxc2 (Mani et al., 2007) were upregulated in CD49f high CD61 high cells by 4.8-, 3.8-, 2.5-and 3.6-folds, respectively ( Figure 6c) . Moreover, increased phosphorylation and total levels of TGFb downstream mediators Smad2/ 3 were observed in CD49f high CD61 high cells compared with CD49f low CD61 low cells (Figure 6d ). Therefore, both gene expression and protein analysis data indicate that the TGFb signaling was further activated in the TICenriched subpopulation. This suggests that the TGFb signaling may have a critical role in Her2-mediated tumorigenesis and maintenance of the TIC population.
To investigate whether expression of the EMT genes in CD49f high CD61 high cells is upregulated concurrently with the TGFb-target genes, we examined the expression status of five canonical EMT genes including Cdh2, Sma, Snail, Twist1 and Zeb1 (Kalluri and Weinberg, 2009 ). All of these genes were expressed in CD49f high CD61 high cells at the highest levels compared with other two subpopulations (Figure 6c ). In addition, Foxc2 analyzed as a TGFb-target gene is also involved in EMT (Mani et al., 2007) . These data show that CD49f high CD61 high cells express the highest TGFb signaling and EMT gene signatures compared with non-TIC-enriched subsets. 
Treatment with TGFb pathway inhibitors suppresses EMT gene expression and concurrently leads to a reduction in the TIC population
To examine the functional relevance of the TGFb signaling in maintenance of the CD49f high CD61 high population, we treated H6O5 cells with two different TGFb-receptor-specific inhibitors, SB431542 and A-83-01. As shown in Figure 7a , these two inhibitors dramatically decreased the CD49f high CD61 high subpopulation by over 70%. This effect was not due to inhibition of overall cell growth ( Supplementary Figure 2) . Nevertheless, the TGFb signaling pathway was significantly inhibited as shown by drastically reduced levels of phosphorylated Smad2/3 ( Supplementary Figure 3) . These data suggest that blockade of the TGFb signaling pathway may preferentially inhibit the self-renewal of TICs. TGFb activity is known to induce an EMT, which can potentially generate cells with stem cell properties (Mani et al., 2008) . We then addressed whether abrogation of the TGFb signaling pathway can lead to suppression of EMT marker gene expression. As shown in Figure 7b (the bottom panel), expression levels of five out of six EMT genes (except Twist1) in drug-treated cells dramatically decreased compared with those in vehicletreated cells. These changes in the EMT gene expression profiles correlated with reverse EMT-like morphological changes in drug-treated cells (Figure 7b, the top panel) . These data suggest that the TGFb receptor inhibitors may preferentially inhibit the expansion of the TIC population by suppressing expression of genes involved in EMT.
To further validate whether the TIC population is reduced by abrogation of the TGFb signaling, we examined clonogenic and tumorsphere-forming abilities of drug-treated cells. Consistent with FACS results (Figure 7a ), 46.1 and 60.5% suppressive extents of tumorsphere formation were observed in SB431542treated and A-83-01-treated cells, respectively, relative to vehicle-treated cells (Figure 7c ). Besides a decrease in tumorsphere number, a significant reduction in sizes of tumorspheres from drug-treated cells was observed (data not shown). Similarly, treatment with SB431542 and A-83-01 resulted in a dramatic reduction in colony formation by 76.8% and 81.9%, respectively (Figure 7d ). These findings, taken together, indicate that the TGFb signaling has an essential role in maintenance of the Her2-transformed TIC population.
Suppression of the integrin-b3 pathway impairs TGFb signaling and self-renewal of TICs
The molecular mechanisms underlying elevated activation of TGFb signaling in the TIC-enriched subpopula- Figure 6 Isolated CD49f high CD61 high cells display the stemness, TGFb signaling and EMT gene signatures. Quantitative reverse transcriptase PCR analyses of stem cell (a), differentiation (b) and TGFb/EMT (c) marker genes were performed on isolated CD49f high CD61 high , CD49f high CD61 low and CD49f low CD61 low H6O5 cells. The mean and s.d. of each gene expression data were derived from triplicate experiments. (d) Enhanced activation of the TGFb signaling pathway in sorted CD49f high CD61 high cells compared with sorted CD49f low CD61 low cells. Western blot analysis of phospho-Smad2 (Ser465/467), total Smad2, phospho-Smad3 (Ser423/425), total Smad3 and actin was performed on protein lysates derived from sorted CD49f high CD61 high and CD49f low CD61 low cells.
The identity of TIC in Her2-induced mammary tumors P-K Lo et al tion are particularly interesting but unknown in our study. It has been shown that integrins are involved in activation of TGFb signaling (Margadant and Sonnenberg, 2010) . Given that the TIC-enriched subpopulation manifests the CD49f high CD61 high trait, it raises the possibility that these two integrin molecules may be implicated in activation of TGFb signaling. Several lines of evidence have shown that avb3-integrin molecules are able to activate the TGFb ligand in vitro and integrin-b3 interacts physically with the TGFb receptor (TGF-bRII) to modulate the TGFb signaling (Scaffidi et al., 2004; Schiemann, 2006, 2007; Wipff et al., 2007) .
To unravel whether integrin-b3 (CD61) is engaged in activating TGFb signaling in H6O5 cells, we performed small interfering RNA (siRNA) knockdown experiments on H6O5 cells. As shown in Figure 8a , siRNAmediated knockdown of CD61 gave rise to decreased phosphorylation of FAK at Tyr397 and c-Src at Tyr416 (the downstream mediators of integrin-b3 signaling), indicating the downstream signaling of integrin b3 was inhibited by CD61 knockdown. Concurrent with reduced integrin-b3 signaling, the TGFb signaling was attenuated by CD61 knockdown, indicated by decreased phosphorylation of Smad2/3 (Figure 8a ). This result demonstrated that CD61 is required for activation of TGFb signaling. We have shown that the TGFb signaling is essential for maintenance of Her2-induced TICs (Figure 7) . This suggests that CD61 may be crucial for maintaining the TIC population. To test it, CD61 siRNA-transfected H6O5 cells were subjected to sphere formation assays compared with untransfected and control siRNA-transfected cells. A decrease of about 30% in sphere formation efficiency was observed in H6O5 cells with CD61 knockdown when compared with control cells (Figure 8b ). These data, taken together, indicate that the cooperative integrin-b3-TGFb signaling axis is mandatory for self-renewal ability of TICs.
Discussion
The growing consensus of the CSC model is attributable to the successful use of surface biomarkers for detecting and enriching CSCs in both human cancers and animal models (Clarke et al., 2006) . However, the fact that no universal markers are able to identify TICs from all types of tumors may partially result from heterogeneous origins of cancer-initiating cells (Visvader, 2011) . Although existence of TICs has been functionally identified in MMTV-Her2/neu tumors (Liu et al., 2007) , no specific markers have been found to enrich them. In our study, combined analysis of CD24, CD49f and ESA revealed that MMTV-Her2/neu-induced mammary tumors are potentially derived from the aberrant mammary luminal progenitor cell population, which is based on these following lines of evidence: (1) The CD24 high CD49f med/low Ma-CFC progenitor population was anomalously expanded in preneoplastic MMTV-Her2/neu mammary glands relative to agematched, normal counterparts (Figure 2a) . (2) The detected, expanded cell population also displayed ESA high (Figure 2a ), a feature similar to human mammary luminal progenitor cells (Lim et al., 2009) .
(3) Gene expression profiles of MMTV-Her2/neu tumor cells are most concordant with the luminal progenitor gene signature (Lim et al., 2010) . Therefore, we for the first time deciphered the potential cell population candidate for the origin of MMTV-Her2/neu mammary tumors. More importantly, we developed a method using the combination of CD49f and CD61 to identify and enrich TICs in MMTV-Her2/neu mammary tumors as well as in Her2-tumor-derived primary cell cultures.
Our data convincingly demonstrate that MMTV-Her2/neu tumors are heterogeneous and CD49f high CD61 high subset cells are enriched for TICs based on both in vitro clonogenic and in vivo transplantation assays. It has been proposed by Vaillant et al. (2008) that MMTV-Her2/neu tumors are composed of a more homogeneous cell population according to FACS analysis. If tumors are composed of homogenous cells, we would expect that there is no correlated cellular distribution between markers, such as ESA, CD24, CD49f and CD61. In contrast to this expectation, the CD49f high CD61 high subset also showed highest expression levels of both CD24 and ESA than other subsets, indicating co-expression of these markers in a TICenriched subset of tumor cells. This notion is further supported by the fact that the stemness, TGFb pathway and EMT gene signatures are specifically, highly expressed in the TIC-enriched subset. Taken together, our results suggest that the CSC model may be still applied to the Her2/neu-induced mouse tumor model.
Through enrichment of TICs in the CD49f high CD61 high subpopulation, we found that the TIC-enriched subpopulation expresses the highest levels of the TGFbresponsive gene signature and exhibits increased TGFb signaling compared with the other subpopulations of tumor cells. This suggests that cells with different phenotypes, even within the same tumor and tissue type, may differentially respond to TGFb receptor inhibitors. Indeed, our results demonstrate that treatment with TGFb receptor inhibitors had no effect on overall cell survival and growth but led to a specific reduction in the TIC population. Analogous to our findings, Shipitsin et al. (2007) found that the TGFb signaling pathway is specifically activated in CD44 þ TICs, and treatment with the TGFb receptor inhibitors had no significant effect on the proliferation and survival of tumor cells but resulted in dramatic morphological changes in CD44 þ cells, similar to mesenchymal-epithelial transition. Taken together, our and other studies further emphasize the importance of the TGFb signaling for maintaining the pool of TICs in both mouse and human mammary tumors.
By knockdown of CD61, we have demonstrated that the integrin-b3 signaling pathway is imperative for Figure 8 Knockdown of integrin-b3 (CD61) leads to a reduction in the TGFb signaling and suppression of TIC self-renewal. (a) Western blot analysis of integrin-b3 and TGFb signaling pathways in H6O5 cells with CD61 knockdown. H6O5 cells were transfected with control or CD61 siRNA, and transfected cells were harvested at 48 h after siRNA transfections for western blot analysis using antibodies against CD61, phospho-focal adhesion kinase (FAK) (Tyr397), total FAK, phospho-c-Src (Tyr416), total c-Src, phospho-Smad2 (Ser465/467), total Smad2, phospho-Smad3 (Ser423/425), total Smad3 and actin. Mouse CD61 siRNA is composed of a pool of four different CD61-specific siRNA duplexes (Dharmacon, Boulder, CO, USA). Untransfected H6O5 cells were also included in the parallel analysis. (b) Tumorsphere formation analysis of CD61-knockdown H6O5 cells. Sphere formation assays were performed on untransfected, control siRNA-transfected and CD61 siRNA-transfected H6O5 cells. *Po0.05 indicates a statistically significant difference. sustaining the TGFb signaling, and the cooperative integrin-b3-TGFb signaling axis has an indispensable role in maintaining Her2-transformed TICs. These findings for the first time provide novel evidence to link the integrin-b3-TGFb signaling mode to TICs and to decipher, at least in part, the mechanisms underlying increased activation of TGFb signaling in TICs. The avb3-integrin-Src signaling axis has been shown to facilitate TGFb-mediated induction of EMT in mammary epithelial cells and promote breast cancer cell proliferation and invasion Schiemann, 2006, 2007) . The oncogenic roles of the avb3-integrin-Src signaling axis in TGFb signaling and EMT may account for our observations that the TIC-enriched CD49f high CD61 high subset exhibited increased TGFb signaling and the typical EMT gene signature. According to accumulating evidence to show the importance of targeting of TICs in cancer therapy, our novel findings linking the integrin-b3-TGFb signaling axis to Her2transformed TICs may have immediate therapeutic implications due to the current testing of TGFb pathway inhibitors and avb3-integrin antagonists in clinical trials (Biswas et al., 2006; Desgrosellier and Cheresh, 2010) .
Materials and methods
Cell isolation and culture Isolation of cancer epithelial cells from mammary tumors of MMTV-Her2/neu transgenic mice and establishment of the primary Her2-overexpressing tumor cell line H6O5 were described previously (Chen et al., 2010) . The procedures for isolating Lin À epithelial cells from mammary glands are described in the Supplementary Materials and methods.
Flow cytometry analysis and sorting FACS analysis was performed using an FC500 CXP flow cytometer (Beckman Coulter, Fullerton, CA, USA). Cells were stained with the following antibodies: FITC-and PEconjugated anti-CD49f (Becton Dickinson, Sparks, MD, USA), Alexa 488-conjugated anti-CD61 (BioLegend, San Diego, CA, USA), PE-and APC-conjugated anti-CD24 (BioLegend) and PE-and APC-Cy7-conjugated anti-ESA (BioLegend). Cell sorting was carried out on a FACSAria II cell sorter (Becton Dickinson).
In vitro clonogenic assays Sorted or drug-treated H6O5 cells were plated in six-well plates at a density of 1000 cells per well or in 6-cm culture dishes at a density of 5000 cells/dish in complete medium. After 2 weeks, colonies were fixed and then stained with 0.1% crystal violet. Colonies with sizes X1 mm were counted.
In vitro tumorsphere formation assays Sorted or drug-treated viable H6O5 cells were plated in ultralow attachment six-well plates (Corning, Acton, MA, USA) at a density of 10 000 cells/ml in serum-free DMEM/F12 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 20 ng/ml epidermal growth factor (Sigma, St Louis, MO, USA), 10 ng/ ml basic fibroblast growth factor (Sigma), 5 mg/ml insulin (Sigma), 1 Â B27 supplement (Invitrogen) and 0.4% bovine serum albumin (Sigma). Cells were cultured under 5% CO 2 at 37 1C for a week (Gu et al., 2011) .
In vivo tumorigenesis assays
Sorted cells were resuspended in 20 ml Dulbecco's modified Eagle's medium/F12 medium and mixed with 20 ml Matrigel (Becton Dickinson) at a 1:1 ratio and held on ice. The entire 40 ml sample was injected into either no. 3 or 4 mammary glands of MMTV-Her2/neu transgenic mice anesthetized with isoflurane according to the animal protocol approved by the University of South Carolina committee for research in vertebrate animals. Tumor sizes were measured weekly. Incidence of xenograft tumor formation was scored 12-13 weeks after injection.
Please see Supplementary Materials and methods for the description of cell isolation, quantitative real-time reverse transcriptase PCR, western blot, cell proliferation, siRNA transfection and statistical analyses.
